## Abstract ## Objective To evaluate the frequency of and determine predictive factors for acute hospitalization in a prospective study of patients with Alzheimer's disease (AD). ## Design A one year prospective study. ## Participants 134 patients recruited from the memory clinic in Toulouse U
Factors associated with mortality in patients with early-onset Alzheimer's disease: a five-year longitudinal study
β Scribed by Akinori Ueki; Hidetaka Shinjo; Hiroko Shimode; Takaya Nakajima; Yoshio Morita
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 69 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0885-6230
- DOI
- 10.1002/gps.419
No coin nor oath required. For personal study only.
β¦ Synopsis
To identify neuropsychiatric and somatic factors related to survival in early-onset Alzheimer's disease, we longitudinally studied 108 patients (35 male, 73 female) with early-onset Alzheimer's disease who were 46 to 64 years old at onset and 50 to 69 years old when diagnosed at our institution. A five-year follow-up, 30 patients had died. Pneumonia was the most common cause (73%), followed by malignancy (20%) and heart disease (7%). Kaplan-Meier survival curves showed a lower survival rate in patients with early-onset Alzheimer's disease than in age- and sex-matched life-table data in Japan. In Cox proportional hazards analysis, male gender, early disease onset, concurrent physical illness at time of diagnosis, and a low mini-mental state examination score increased the likelihood of death in patients with early-onset Alzheimer's disease. Our study confirmed that these patients have considerable excess mortality and a different pattern of cause of death than in the general population. Gender, age at onset, physical illness, and cognitive function strongly influenced survival. These factors may be predictors of mortality in patients with early-onset Alzheimer's disease that are useful in counseling patients and their families.
π SIMILAR VOLUMES
## Abstract ## Objective To evaluate the longβterm frequency of disease remissions and the progression of joint damage in patients with early rheumatoid arthritis (RA) who were initially randomized to 2 years of treatment with either a combination of 3 diseaseβmodifying antirheumatic drugs (DMARDs